Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) (COR-SHOCK)

15 maggio 2026 aggiornato da: João Presume, Hospital de Santa Cruz, Portugal

Cardiovascular Outcomes Registry in Cardiogenic SHOCK

The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:

  • How have management strategies and clinical outcomes for cardiogenic shock evolved over time?
  • How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?

Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.

Participants will:

  • Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced).
  • Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay.
  • Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.

Panoramica dello studio

Descrizione dettagliata

The Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) is hybrid (retrospective and prospective), observational registry designed to evaluate the clinical performance, therapeutic management, and outcomes of patients presenting with cardiogenic shock (CS).

Contemporary CS management has evolved beyond correcting macro-hemodynamic parameters. CS is now recognized as a highly dynamic, systemic syndrome characterized by microvascular hypoperfusion, systemic inflammatory response syndrome (SIRS), endothelial dysfunction, and profound neurohormonal and metabolic derangements. To capture this complexity, the COR-SHOCK registry systematically integrates granular, real-world data reflecting these pathophysiological axes. This includes laboratory evaluation, and advanced invasive hemodynamic profiling via pulmonary artery catheterization (Swan-Ganz).

Registry Procedures and Quality Assurance Plan

To ensure high-quality data collection and compliance with scientific standards, the registry implements the following procedures:

  1. Quality Assurance (QA) Plan:

    The Steering Committee, led by the Principal Investigator, oversees the registry's operations. Internal data quality audits are conducted semi-annually to review enrollment rates, evaluate protocol adherence, and identify systematic data entry discrepancies.

  2. Data Checks:

    Data is transcribed from electronic health records into a dedicated electronic database. The entry platform utilizes programmed range validation and consistency rules (e.g., preventing physiological out-of-range values for hemodynamics and laboratory results, and enforcing logical chronological order for clinical events, such as ensuring discharge dates succeed admission dates).

  3. Source Data Verification (SDV):

    To guarantee data accuracy and completeness, a designated researcher who is not directly involved in the primary data entry performs random source data verification on 10% of all registry entries. This process involves cross-referencing database records with original paper and electronic health records.

  4. Data Dictionary:

    A comprehensive data dictionary has been established, detailing every variable collected. It defines clinical terminology, laboratory reference ranges, and standardized categorization rules.

  5. Standard Operating Procedures (SOPs):

    Formal SOPs govern all key registry processes, including:

    • Daily screening and identification of eligible patients in the cardiac intensive care unit (UNICOR).
    • Standardized timing for dynamic data collection.
    • Data security protocols, including patient pseudonymization and password-protected access control.
    • Event reporting protocols for predefined clinical complications.
  6. Sample Size Assessment:

The registry aims to include approximately 750 to 800 patients. This target is calculated based on historical admission rates at the center, comprising a retrospective cohort of approximately 500 patients (2017-2025) and a prospective recruitment target of 80 to 100 patients annually over a 2-to-3-year period. This sample size provides sufficient statistical power to characterize temporal trends, evaluate subset populations (e.g., mechanical circulatory support, specific etiologies), and perform robust multivariable risk modeling.

Statistical Analysis Plan (SAP) Descriptive statistics will characterize the study population. Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), based on normality (assessed via Shapiro-Wilk test). Categorical variables will be expressed as frequencies and percentages.

To evaluate management and outcome trends over the years:

  • Temporal trends in clinical management, therapeutic choices (such as the use of short-duration mechanical circulatory support [VA-ECMO, Impella, IABP] or advanced therapies [LVAD, cardiac transplantation]), and survival will be assessed using linear/logistic regression models across calendar years.
  • Survival curves will be estimated using the Kaplan-Meier method and compared across different clinical phenotypes, therapeutic interventions, and time epochs using the log-rank test.
  • Multivariable Cox proportional hazards regression and logistic regression models will be constructed to identify independent clinical, laboratory and hemodynamic predictors of short-term (ICU and in-hospital) and long-term (1 year) mortality. Model fit and calibration will be evaluated using standard diagnostic metrics (e.g., Harrell's C-index).

Tipo di studio

Osservativo

Iscrizione (Stimato)

800

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consists of adult patients admitted with cardiogenic shock. The population reflects a real-world, highly complex, and critically ill cohort comprising both a retrospective cohort (admitted from January 2017 onwards) and a prospective cohort consecutively enrolled at the center.

Descrizione

Inclusion Criteria:

-Cardiogenic shock according to the following criteria:

Cardiac disorder resulting in hypotension, defined as at least one of the following:

  • Systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or
  • Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg

AND

Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:

  • Serum lactate >2 mmol/L
  • Acute kidney injury and/or oliguria
  • Acute hepatic injury
  • Cool or mottled extremities
  • Altered mental status

AND

Clinical presentation judged to be primarily attributable to a cardiac etiology.

Exclusion Criteria:

  • Age < 18 years.
  • Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).
  • Refusal to participate in the study (applicable only to the prospective cohort).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Cardiogenic Shock Registry Cohort
Adult patients admitted with a diagnosis of cardiogenic shock between January 2017 and the end of the prospective recruitment period. All patients receive contemporary, standard clinical management for cardiogenic shock as determined by the clinical team, with no experimental interventions. Clinical, laboratory, imaging, and advanced hemodynamic monitoring data are systematically collected from hospital records to evaluate clinical performance and outcomes over time.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
All-Cause Mortality at 30 days after admission
Lasso di tempo: From date of hospital admission to 30 days after admission
The proportion of patients presenting with cardiogenic shock who die from any cause during the first 30 days after admission
From date of hospital admission to 30 days after admission

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
All-Cause Mortality at 1 Year
Lasso di tempo: At 1 year post-index admission.
The rate of all-cause mortality evaluated after the index admission. Survival status will be determined via electronic medical records or the national registry ("last seen alive" verification).
At 1 year post-index admission.
Incidence of Major Bleeding up to 30 days after admission
Lasso di tempo: From date of hospital admission to 30 days after admission
The proportion of patients experiencing major bleeding events up to 30 days after admission. Major bleeding is defined according to the Bleeding Academic Research Consortium (BARC) classification as Type 3 (including 3a, 3b, and 3c) or Type 5 (fatal bleeding).
From date of hospital admission to 30 days after admission
Incidence of 3-Point Major Adverse Cardiovascular Events (3P-MACE) at 30 days
Lasso di tempo: From date of hospital admission to 30 days after admission
Thrombotic/ischemic events are defined using the 3-point Major Adverse Cardiovascular Events (3P-MACE) composite, which includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke at 30 days after admission.
From date of hospital admission to 30 days after admission

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of Long-term Ventricular Assist Device (LVAD) Implantation or Heart Transplantation
Lasso di tempo: Up to 1 year post-index admission.
The percentage of patients transitioning to advanced, long-term therapeutic options, specifically durable Left Ventricular Assist Devices (LVAD, e.g., HeartMate 3) or undergoing heart transplantation as a bridge or destination therapy.
Up to 1 year post-index admission.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

31 dicembre 2030

Completamento dello studio (Stimato)

31 dicembre 2030

Date di iscrizione allo studio

Primo inviato

9 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 maggio 2026

Primo Inserito (Effettivo)

19 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual Participant Data (IPD) will not be publicly shared to protect patient confidentiality and ensure strict compliance with legal and ethical standards. This study is conducted in accordance with the European Union General Data Protection Regulation (GDPR) and Portuguese Data Protection Law (Lei n.º 58/2019).

De-identified, aggregated data or specific proposals for collaborative academic research may be considered upon reasonable request, subject to approval by the study's Steering Committee and the institutional Ethics Committee (contact via jppereira@ulslo.min-saude.pt).

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Shock cardiogenico

Sottoscrivi